TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21935916
Drug: Eribulin 1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eribulin 1.4 mg/m(2) administered intravenously on days 1 and 8 every 21 days in platinum-sensitive cohort
Study: 21937277
Drug: Eribulin (1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eribulin (1.4 mg/m² intravenously on days 1 and 8 every 3 weeks)
Study: 21937701
Drug: Lenalidomide 25
Normalized name: lenalidomide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 25 mg/d on days 1-21 of a 28-day cycle
Study: 21940838
Drug: Peginesatide (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginesatide (various doses based on body weight or absolute doses, administered either intravenously or subcutaneously, every 4 or 2 weeks)
Study: 21940838
Drug: Peginesatide (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginesatide (various doses)
Study: 21942531
Drug: SDP (SUMAVEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDP (SUMAVEL DosePro) administered for ≤4 migraine attacks over ≤60 days
Study: 21942991
Drug: Implementation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implementation of guidelines for systematic daily pain assessments following the educational intervention.
Study: 21945953
Drug: Infliximab therapy
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab therapy discontinued
Study: 21945953
Drug: Infliximab re-treatment
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab re-treatment after relapse
Study: 21948234
Drug: Historical controls
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical controls (identically treated except for T1/T2 product infusions)
Study: 21953248
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg daily and bevacizumab 10 mg/kg on days 1 and 15 every 28 days
Study: 21953853
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonist (VKA) therapy for patients with RVT for up to 2 years
Study: 21953853
Drug: No VKA
Approvals — FDA: no, EMA: no, PMDA: no
Description: No VKA therapy for patients without RVT
Study: 21958326
Drug: B-type natriuretic
Normalized name: B-type natriuretic peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: B-type natriuretic peptide (BNP) in TnT positive patients (TnT > 0.01 ng/mL) in the highest quartile (Q4)
Study: 21964801
Drug: Panobinostat 10
Normalized name: panobinostat 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panobinostat 10 mg/m²
Study: 21964801
Drug: Panobinostat 15
Normalized name: panobinostat 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panobinostat 15 mg/m²
Study: 21964801
Drug: Panobinostat 20
Normalized name: panobinostat 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panobinostat 20 mg/m²
Study: 21964801
Drug: Panobinostat (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panobinostat (all doses)
Study: 21965374
Drug: DEX-brief (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX-brief (2 mcg/kg bolus over 10 minutes)
Study: 21965374
Drug: DEX-prolong (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX-prolong (2 mcg/kg bolus plus 1 mcg/kg/hr infusion as needed)
Study: 21967976
Drug: Intravenous clofarabine
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous clofarabine 40 mg/m(2) per day, cyclophosphamide 440 mg/m(2) per day, etoposide 100 mg/m(2) per day for 5 consecutive days
Study: 21967976
Drug: Intravenous clofarabine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous clofarabine, cyclophosphamide, and etoposide
Study: 21968545
Drug: Regadenoson (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regadenoson (0.4 mg/5 ml bolus)
Study: 21968545
Drug: Adenosine (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (140 μg/kg/min)
Study: 21969517
Drug: Nab-paclitaxel 125
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel 125 mg/m² plus gemcitabine 1,000 mg/m²
Study: 21975221
Drug: Blood manganese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood manganese levels in patients with hepatic encephalopathy (median, range) [28, (17-39.5) μg/L] for those who died after 6 months follow-up.
Study: 21975221
Drug: Blood manganese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood manganese levels in patients with hepatic encephalopathy (median, range) [13.5, (10.5-32) μg/L] for those who survived after 6 months follow-up.
Study: 21975221
Drug: Blood manganese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood manganese levels in patients with hepatic encephalopathy (median, range) [20.5, (10.5-39.5) μg/L].
Study: 21976132
Drug: Dasatinib 50
Normalized name: dasatinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib 50 to 120 mg once daily and docetaxel 60 to 75 mg/m² every 21 days (phase 1)
Study: 21976132
Drug: Dasatinib 100
Normalized name: dasatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib 100 mg once daily and docetaxel 75 mg/m² every 21 days (phase 2)
Study: 21976132
Drug: Single-agent dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single-agent dasatinib after docetaxel discontinuation
Study: 21976540
Drug: Dovitinib (TKI258)
Normalized name: Dovitinib
DrugBank: Dovitinib (DB05928)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dovitinib (TKI258) at 400 mg/d
Study: 21976672
Drug: Barasertib 1200
Normalized name: Barasertib
DrugBank: Barasertib (DB11747)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barasertib 1200 mg
Study: 21976672
Drug: Barasertib 800
Normalized name: Barasertib
DrugBank: Barasertib (DB11747)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barasertib 800 mg, 1200 mg, and 1600 mg
Study: 21977353
Drug: Desvenlafaxine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine (200 to 400 mg/d)
Study: 21977355
Drug: Physician counseling
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physician counseling that medication use was safe despite FDA warning
Study: 21982650
Drug: Real-world treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real-world treatment including rate and rhythm control, stroke prevention, transitions to new therapies
Study: 21983216
Drug: PCV13 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCV13 (2 doses for group 1, 1 dose for group 2)
Study: 21986722
Drug: Carboplatin (AUC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (AUC 4 mg/ml-min), Irinotecan (340 mg/m2 for patients on EIAEDs, 125 mg/m2 for others), Bevacizumab (10 mg/kg)
Study: 21986736
Drug: Proinflammatory sex
Normalized name: Arthriten Inflammatory Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proinflammatory sex hormone profile (low testosterone and high estradiol)
Study: 21987241
Drug: Maraviroc 150
Normalized name: maraviroc 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maraviroc 150 mg twice daily for 14 days
Study: 21991891
Drug: Inhaled glucocorticoids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled glucocorticoids
Study: 21991892
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with bronchodilator reversibility
Study: 21992630
Drug: Zilver PTX
Normalized name: PTX-100
DrugBank: PTX-100 (DB18125)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zilver PTX drug-eluting stent
Study: 21992853
Drug: Aflibercept 6
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aflibercept 6 mg/kg intravenously plus docetaxel 75 mg/m(2) intravenously, every 3 weeks
Study: 21993671
Drug: Phlebotomy therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phlebotomy therapy in VHL(R200W) homozygotes
Study: 21994418
Drug: ALT-801 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALT-801 at 0.04 mg/kg
Study: 21994418
Drug: ALT-801 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ALT-801 treatment
Study: 21998698
Drug: RTS,S/AS01(E) vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01(E) vaccine
Study: 21999176
Drug: Prefilled pen
Normalized name: Byetta Prefilled Pen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prefilled pen for IM IFNβ-1a administration
Study: 22002941
Drug: Methylation-promoting dietary
Normalized name: methylal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylation-promoting dietary supplements (betaine, metafolin, creatine, and vitamin B(12))
Study: 22003383
Drug: NMRC-M3V-Ad-PfCA vaccine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: NMRC-M3V-Ad-PfCA vaccine, 2×10^10 particle units (1×10^10 each construct)
Study: 22003383
Drug: NMRC-M3V-Ad-PfCA vaccine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: NMRC-M3V-Ad-PfCA vaccine, 5-fold higher dose (10×10^10 particle units)
Study: 22003383
Drug: NMRC-M3V-Ad-PfCA vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NMRC-M3V-Ad-PfCA vaccine
Study: 22003411
Drug: NMRC-MV-Ad-PfC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NMRC-MV-Ad-PfC vaccine (adenovirus vector encoding CSP), 1 x 10^10 particle units per dose, two doses 16 weeks apart
Study: 22003411
Drug: NMRC-MV-Ad-PfC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NMRC-MV-Ad-PfC vaccine (adenovirus vector encoding CSP)
Study: 22004373
Drug: Non-surgical treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical treatment by a doctor
Study: 22005144
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy (PCT) with surgery, based mainly on a fluorouracil-platinum doublet or triplet regimen.
Study: 22005144
Drug: Primary surgery
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary surgery (S) without perioperative chemotherapy.
Study: 22005144
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy after surgery in the S group.
Study: 22005144
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy after surgery in the PCT group.
Study: 22005144
Drug: PCT as
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCT as a treatment.
Study: 22006233
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of autologous platelet-rich fibrin matrix (PRFM) into the deep dermis and subdermis of the skin.
Study: 22008340
Drug: Topical rThrombin
Normalized name: rThrombin
DrugBank: rhThrombin (DB04923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical rThrombin applied as a hemostatic aid during surgical procedure (day 1)
Study: 22011412
Drug: Autologous umbilical
Normalized name: Autologous umbilical cord blood
DrugBank: Autologous cord blood (DB17926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous umbilical cord blood (UCB) infusion
Study: 22011459
Drug: FDG PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDG PET/CT after one cycle of neoadjuvant chemotherapy
Study: 22012004
Drug: Genexol-PM 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genexol-PM 240 mg/m(2) intravenously over 3 h every 3 weeks, with intra-patient dose escalation to 300 mg/m(2) allowed if no pre-specified toxicities were observed.
Study: 22013821
Drug: Paper-based prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paper-based prescriptions (control group)
Study: 22014006
Drug: Pazopanib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib and metronomic oral cyclophosphamide
Study: 22015991
Drug: Sorafenib dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib dose escalation to 600 mg BID through cycle 2
Study: 22015991
Drug: Sorafenib dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib dose re-escalation to 400 mg BID through cycle 3
Study: 22015991
Drug: Completion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Completion of cycle 1 without dose modification or discontinuing treatment
Study: 22015991
Drug: Primary dose
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary dose escalation through cycle 2
Study: 22018074
Drug: Daily vitamin
Normalized name: Daily Vitamin Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily vitamin D supplementation
Study: 22021722
Drug: Amoxicillin and
Normalized name: omeprazole, amoxicillin and rifabutin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin and Clavulanic Acid (antibiotic therapy)
Study: 22021788
Drug: Tight glycaemic
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tight glycaemic control (intravenous, then subcutaneous insulin to control blood glucose to 4.4-6.5 mmol/l)
Study: 22021870
Drug: Manual Physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual Physical Therapy (MPT) - 6 sessions
Study: 22021870
Drug: Corticosteroid Injections
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid Injections (CSI) - 1 to 3 sessions
Study: 22021873
Drug: Viusid (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viusid (three oral sachets daily, n=50)
Study: 22024527
Drug: HIV RNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV RNA ≥ 4 log₁₀ copies/ml at failure.
Study: 22025149
Drug: R1507 9
Approvals — FDA: no, EMA: no, PMDA: no
Description: R1507 9 mg/kg intravenously once a week
Study: 22025149
Drug: R1507 27
Approvals — FDA: no, EMA: no, PMDA: no
Description: R1507 27 mg/kg intravenously every three weeks
Study: 22025151
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy with oxaliplatin 85 mg/m(2) on days 1, 15, and 29; protracted-infusion fluorouracil (PI-FU) 180 mg/m(2)/d on days 8 through 43; external-beam radiation therapy (EBRT) 5 days a week at 1.8 Gy/d for 25 fractions
Study: 22025151
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy with oxaliplatin, PI-FU, and EBRT
Study: 22025154
Drug: Figitumumab at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Figitumumab at 30 mg/kg intravenously every 4 weeks for a median of 2 cycles (range, 1 to 16)
Study: 22025154
Drug: Figitumumab at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Figitumumab at 30 mg/kg with baseline free IGF-1 ≥ 0.65 ng/mL
Study: 22025154
Drug: Figitumumab at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Figitumumab at 30 mg/kg with pretreatment circulating free IGF-1 lower than 0.65 ng/mL
Study: 22025196
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate 45 mg 6-month depot
Study: 22025778
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of crown-like structures (CLS) in subcutaneous adipose tissue (n = 16)
Study: 22028492
Drug: L19-IL2 in
Normalized name: DAB(SUB 389)IL2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L19-IL2 in combination with dacarbazine
Study: 22030215
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion at a constant rate for the first 12 hours, then titrated between 0.1 and 2.5 μg/kg/h for up to 14 days.
Study: 22030975
Drug: Swallowing 14.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swallowing 14.5 ml of water
Study: 22030975
Drug: Swallowing 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swallowing 20 ml of water
Study: 22030975
Drug: Swallowing 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swallowing 100 ml of water
Study: 22033282
Drug: Mocetinostat 110
Normalized name: Mocetinostat
DrugBank: Mocetinostat (DB11830)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mocetinostat 110 mg, administered orally three times per week
Study: 22033282
Drug: Mocetinostat 85
Normalized name: Mocetinostat
DrugBank: Mocetinostat (DB11830)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mocetinostat 85 mg, administered orally three times per week
Study: 22033282
Drug: Mocetinostat 110
Normalized name: Mocetinostat
DrugBank: Mocetinostat (DB11830)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mocetinostat 110 mg
Study: 22033282
Drug: Mocetinostat 85
Normalized name: Mocetinostat
DrugBank: Mocetinostat (DB11830)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mocetinostat 85 mg
Study: 22033322
Drug: Temsirolimus 75
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Temsirolimus 75 mg/m(2) administered once weekly until disease progression or intolerance
Study: 22033493
Drug: Sequential azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sequential azacitidine and lenalidomide
Study: 22033636
Drug: Sorafenib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 400 mg/bid continuously and 5-fluorouracil 200 mg/sqm/daily day 1-14 every 3 weeks
Study: 22034233
Drug: Concurrent septoplasty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent septoplasty during endoscopic sinus surgery (ESS) (n = 108)
Study: 22034233
Drug: Concurrent septoplasty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent septoplasty during endoscopic sinus surgery (ESS)
Study: 22035417
Drug: Yttrium-90 ibritumomab
Normalized name: yttrium
DrugBank: Yttrium Y-90 (DB13076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yttrium-90 ibritumomab tiuxetan consolidation treatment after R-CHOP chemotherapy
Study: 22035806
Drug: Paclitaxel (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (175 mg/m(2)) and carboplatin (AUC=6.0-7.5) every 21 days for 3 doses, followed by radiation therapy, followed by an additional 3 cycles of paclitaxel and carboplatin (AUC=5-6)
Study: 22036135
Drug: Uric acid
Normalized name: Uric acid
DrugBank: Uric acid (DB08844)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uric acid ≥ 5.0 mg/dL
Study: 22036634
Drug: bosutinib therapy
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: bosutinib therapy
Study: 22037543
Drug: Sublingual temperature
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual temperature measurement
Study: 22038064
Drug: Weight loss
Normalized name: HERBAL WEIGHT LOSS AID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight loss therapy for 1 year
Study: 22040109
Drug: BM-MNC as
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BM-MNC as a cell therapy product
Study: 22044606
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m(2) and carboplatin AUC 6
Study: 22045986
Drug: Intratumoral injection
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intratumoral injection of a TLR9 agonist combined with radiation
Study: 22047558
Drug: AP1903 (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP1903 (a small-molecule dimerizing drug)
Study: 28403055
Drug: PHiD-CV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHiD-CV vaccine
Study: 22050371
Drug: Adjunctive levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adjunctive levetiracetam (LEV) at individualized doses (1,000-4,000 mg/day; 20-80 mg/kg/day for children/adolescents weighing <50 kg)
Study: 22050371
Drug: Adjunctive levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adjunctive levetiracetam (LEV)
Study: 22050987
Drug: Urine albumin
Normalized name: urine albumin test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urine albumin to creatinine ratio categories (≤ 10 mg/g, 11-29 mg/g, 30-299 mg/g, ≥ 300 mg/g)
Study: 22052198
Drug: Protocol-driven treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol-driven treatment (fixed metformin and glargine, insulin adjusted according to sliding scale)
Study: 22052619
Drug: Temozolomide 200
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide 200 mg/m(2) orally for 7 days every 4 weeks (methylated MGMT - mMGMT)
Study: 22052619
Drug: Temozolomide 100
Normalized name: temozolomide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temozolomide 100 mg/m(2) orally for 14 days followed by 200 mg/m(2) orally for 7 days every 6 weeks (unmethylated MGMT - unMGMT)
Study: 22056381
Drug: IL-12 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-12 treatment
Study: 22056644
Drug: High-dose immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose immunosuppressive therapy (HDIT) followed by autologous hematopoietic cell transplantation (AHCT)
Study: 22058200
Drug: Lenalidomide 25
Normalized name: lenalidomide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 25 mg/day (days 1-21 of each 28-day cycle) and dexamethasone (40 mg/day on days 1, 8, 15, and 22) for up to 12 months
Study: 22058224
Drug: Platelet count
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet count in the first quartile on treatment day 33
Study: 22058224
Drug: Platelet counts
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet counts after induction treatment
Study: 22067102
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily insulin regimen with long acting insulin analogue (LAIA) at dinner
Study: 22067102
Drug: Three times
Normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three times daily insulin regimen (standard TID regimen)
Study: 22067102
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily insulin regimen with LAIA at dinner
Study: 22068254
Drug: Metreleptin treatment
Normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metreleptin treatment (subcutaneous injections once or twice daily)